Compare Capri Holdings Ltd (CPRI) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Enveric Biosciences Inc — how do they compare? Capri Holdings Ltd trades at $14.69 (market cap $1.67B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Capri Holdings Ltd is far larger — about 249.6× Enveric Biosciences Inc's market cap, and Capri Holdings Ltd is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Enveric Biosciences Inc for 14 Days on average.
| CPRI | ENVB | |
|---|---|---|
Market Cap | $1.67B | $6.69M |
Volume | 3,722,279 | 41,141 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $10.80 |
52-Week Low | $12.71 | $1.27 |
Typical Hold Time | 41 Days | 14 Days |
Enterprise Value | $2.95B | -$1.60M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.44, down 1.57% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $1.18 billion in 2025, though recent quarters have consistently beaten EPS estimates. Revenue has declined from $5.7 billion in 2022 to $4.44 billion in 2025, but management expects second-half growth driven by brand revitalization efforts at Michael Kors and Jimmy Choo.
The stock presents a mixed outlook with a low P/S ratio of 0.5 and a consensus price target of $20.57 offering potential upside. However, significant risks include persistent revenue declines, high debt levels, and competitive pressures in the luxury sector. Analyst sentiment is divided with 44% buy ratings versus 52% hold, reflecting uncertainty about the turnaround timeline.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
